Monday, November 28, 2016

BRIEF-Blueprint Medicines announces Proof-of-Concept Data from Global Phase 1 clinical trial of BLU-554 in patients with advanced Hepatocellular Carcinoma

* Blueprint Medicines announces proof-of-concept data from

global phase 1 clinical trial of BLU-554 in patients with

advanced Hepatocellular Carcinoma

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)